The clearance comes just a week after BlueStar received its 10th FDA clearance for using connected insulin dosing data in personalized bolus insulin dosing recommendations. Welldoc’s newest clearance enables BlueStar to provide bolus insulin dose recommendations based on continuous glucose readings.
BlueStar can now offer dose recommendations based on the most recent glucose reading and rate of change from a compatible CGM. This feature enhances BlueStar’s existing digital coaching capabilities for guiding dietary and lifestyle decisions in diabetes management.
Get the full story at our sister site, Drug Delivery Business News.